AUPH
Aurinia Pharmaceuticals Inc.
$15.22
-0.23
(-1.49%)
Mkt Cap
1.96B
Volume
957,149
52W Range
7.285-16.88
Sector
Healthcare
Beta
1.45
EPS (TTM)
2.24
P/E Ratio
6.79
Revenue (TTM)
298.30M
Rev Growth (5Y)
+41.4%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
$28.74
Undervalued · Strong
47.0% below fair value
AlphaQuality · Grade · Gated
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
Company Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 283.06M | 235.13M | 175.51M | 134.03M | 45.60M | 50.12M | 318,000 | 463,000 | 420,000 | 173,000 | 235,000 | 278,000 |
| Net Income | 287.20M | 5.75M | (78.02M) | (108.18M) | (180.97M) | (102.68M) | (88.39M) | (64.12M) | (70.79M) | (23.30M) | (18.61M) | (16.65M) |
| EPS | 2.14 | 0.04 | -0.54 | -0.76 | -1.40 | -0.87 | -1.33 | -0.76 | -0.92 | -0.66 | -0.58 | -0.57 |
| Free Cash Flow | 135.41M | 44.11M | (34.18M) | (79.82M) | (159.19M) | (77.20M) | (63.69M) | (51.69M) | (41.19M) | (18.74M) | N/A | N/A |
| FCF / Share | 1.01 | 0.31 | -0.24 | -0.56 | -1.23 | -0.65 | -0.68 | -0.61 | -0.54 | -0.53 | N/A | N/A |
| Operating CF | 135.66M | 44.39M | (33.46M) | (79.53M) | (157.69M) | (69.86M) | (63.59M) | (51.61M) | (41.17M) | (18.71M) | N/A | N/A |
| Total Assets | 751.59M | 550.64M | 548.06M | 470.86M | 543.37M | 463.66M | 324.30M | 145.86M | 189.85M | 57.00M | N/A | N/A |
| Total Debt | 74.81M | 79.37M | 97.61M | 8.09M | 8.74M | 8.41M | 0 | 0 | 0 | 0 | N/A | N/A |
| Cash & Equiv | 80.21M | 83.43M | 48.88M | 94.17M | 231.90M | 272.35M | 306.02M | 117.97M | 165.63M | 39.65M | N/A | N/A |
| Book Value | 581.33M | 377.48M | 377.95M | 405.44M | 479.09M | 407.75M | 298.60M | 112.58M | 165.74M | 35.95M | N/A | N/A |
| Return on Equity | 0.49 | 0.02 | -0.21 | -0.27 | -0.38 | -0.25 | -0.30 | -0.57 | -0.43 | -0.65 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.70M | 77.11M | 73.47M | 70.01M | 62.47M | 59.87M | 67.77M | 57.19M | 50.30M | 45.09M | 54.52M | 41.49M |
| Net Income | 34.35M | 210.79M | 31.55M | 21.51M | 23.34M | 1.43M | 14.35M | 722,000 | (10.75M) | (26.88M) | (13.45M) | (11.49M) |
| EPS | 0.26 | 1.58 | 0.24 | 0.16 | 0.16 | 0.01 | 0.10 | 0.01 | -0.07 | -0.19 | -0.09 | -0.08 |
| Free Cash Flow | 32.52M | 44.50M | 44.38M | 44.14M | 1.28M | 30.06M | 16.94M | 15.71M | (18.61M) | 14.25M | (13.17M) | (3.05M) |
| FCF / Share | 0.25 | 0.33 | 0.32 | 0.32 | 0.01 | 0.21 | 0.12 | 0.11 | -0.13 | 0.10 | -0.09 | -0.02 |
| Operating CF | 32.56M | 44.57M | 44.45M | 44.24M | 1.30M | 30.11M | 17.03M | 15.84M | (18.60M) | 14.31M | (13.28M) | (2.83M) |
| Total Assets | 724.00M | 751.59M | 527.53M | 502.56M | 504.85M | 550.64M | 549.36M | 523.53M | 516.63M | 548.06M | 555.01M | 548.90M |
| Total Debt | 68.64M | 74.81M | 78.21M | 81.83M | 77.91M | 79.37M | 87.85M | 85.98M | 88.54M | 97.61M | 93.21M | 101.21M |
| Cash & Equiv | 41.01M | 80.21M | 73.19M | 53.00M | 66.43M | 83.43M | 37.14M | 33.41M | 64.46M | 48.88M | 46.40M | 81.71M |
| Book Value | 567.63M | 581.33M | 365.77M | 335.30M | 350.19M | 377.48M | 388.00M | 364.62M | 359.48M | 377.95M | 391.88M | 392.29M |
| Return on Equity | 0.06 | 0.36 | 0.09 | 0.06 | 0.07 | 0.00 | 0.04 | 0.00 | -0.03 | -0.07 | -0.03 | -0.03 |
AUPH News
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
Parabolic AI rally has bulls eyeing a comeback for this one-time meme metal trade
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals (NASDAQ:AUPH) vs. Cronos Group (NASDAQ:CRON) Financial Comparison
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of “Hold” by Analysts
SG Americas Securities LLC Grows Position in Aurinia Pharmaceuticals Inc $AUPH
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance
MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition